Cancer Treatment Affordability
-
{
- All
- News
-
Cancer Drug Prices Slashed By Up To 96.45%; Annual Consumer Savings Pegged At Rs 3,540 Crore: Government
The government on Monday said revised prices of 1,364 anti-cancer drug formulations have come into effect, with consumers expected to save an estimated Rs 3,540.38 crore annually following a cap on trade margins for 137 anti-cancer drugs.
-
Government Cancer Drug Price Curb Likely To Create Rs 3,357 Crore Savings Estimate
India's move to cap trade margins on 137 non-scheduled anti-cancer medicines has led 70 companies to cut maximum retail prices by an average 20 per cent to 70 per cent on 120 medicines, with estimated patient savings of Rs 3,357.49 crore, an official factsheet said on Friday.
-
India's Cancer Affordability: Cheaper Drugs Alone Cannot Save More Lives
Price control is not the answer to India's cancer problem. What it needs is a comprehensive strategy of transparent pharmaceutical pricing, indigenous innovation, rational treatment protocols, evidence-based reimbursement and equitable health care delivery.
-
Cancer Drug Prices Slashed: New Rates For 543 Drug Brands From November 9
The new MRPs will apply from November 9, 2026. The NPPA's latest list is based on the price information submitted by companies until October 27.
-
Supreme Court Flags Massive Gap Between Medicine MRP And Retailer Cost, Asks Government, "Allowing This To Happen?"
The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain seeking mandatory generic drug prescriptions, strict initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).
-
4 Years After Her Death, Court Says Centre Can Make Cancer Drug She Needed
The Kerala High Court held that the Centre has the power under the Patents Act to manufacture patented life-saving medicines and sell them at cheaper rates to patients who cannot afford them - a ruling that came after a petition filed by a cancer patient who died before her case could be heard.
-
Cancer Drug Prices Slashed By Up To 96.45%; Annual Consumer Savings Pegged At Rs 3,540 Crore: Government
The government on Monday said revised prices of 1,364 anti-cancer drug formulations have come into effect, with consumers expected to save an estimated Rs 3,540.38 crore annually following a cap on trade margins for 137 anti-cancer drugs.
-
Government Cancer Drug Price Curb Likely To Create Rs 3,357 Crore Savings Estimate
India's move to cap trade margins on 137 non-scheduled anti-cancer medicines has led 70 companies to cut maximum retail prices by an average 20 per cent to 70 per cent on 120 medicines, with estimated patient savings of Rs 3,357.49 crore, an official factsheet said on Friday.
-
India's Cancer Affordability: Cheaper Drugs Alone Cannot Save More Lives
Price control is not the answer to India's cancer problem. What it needs is a comprehensive strategy of transparent pharmaceutical pricing, indigenous innovation, rational treatment protocols, evidence-based reimbursement and equitable health care delivery.
-
Cancer Drug Prices Slashed: New Rates For 543 Drug Brands From November 9
The new MRPs will apply from November 9, 2026. The NPPA's latest list is based on the price information submitted by companies until October 27.
-
Supreme Court Flags Massive Gap Between Medicine MRP And Retailer Cost, Asks Government, "Allowing This To Happen?"
The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain seeking mandatory generic drug prescriptions, strict initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).
-
4 Years After Her Death, Court Says Centre Can Make Cancer Drug She Needed
The Kerala High Court held that the Centre has the power under the Patents Act to manufacture patented life-saving medicines and sell them at cheaper rates to patients who cannot afford them - a ruling that came after a petition filed by a cancer patient who died before her case could be heard.
